See What HealthDay Can Do For You
Contact Us

Fluticasone May Improve Eosinophilic Esophagitis

Half of patients treated with fluticasone showed histologic remission

TUESDAY, Nov. 28 (HealthDay News) -- Oral doses of fluticasone propionate can reduce symptoms and promote histologic remission in pediatric patients with eosinophilic esophagitis, according to the results of a randomized, double-blind and placebo-controlled trial published in the November issue of Gastroenterology.

Marc E. Rothenberg, M.D., Ph.D., of Cincinnati Children's Hospital Medical Center in Ohio, and colleagues randomized 36 patients, aged 3 to 18 years, who had active eosinophilic esophagitis to either 880 micrograms of fluticasone propionate or placebo twice daily for three months.

Fifty percent of patients receiving fluticasone propionate showed histologic remission, determined by peak eosinophil count in the esophageal epithelium, compared with only 9 percent in the placebo group. Fluticasone reduced eosinophil levels and reduced vomiting, a common symptom of eosinophilic esophagitis. Non-allergic and younger individuals showed the most benefit.

"With its ease of administration and favorable side-effect profile, fluticasone propionate is an attractive therapy for the treatment of patients with eosinophilic esophagitis," the authors conclude. The study results also suggest that eosinophilia can be driven by food allergens, according to an editorial by Glenn Furuta, M.D., of Children's Hospital Boston.

Abstract
Full Text (subscription or payment may be required)
Editorial

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.